Clinical trial · Observational
Registry Platform Gastric/Esophageal Cancer (SAPHIR)
Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy
NCT04290806CI-TRIAL-00101836SAPHIRrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Esophageal Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastric Adenocarcinoma | Gastric Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gastroesophageal Junction Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine care as per site standard | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- ESCC
- description
- 250 patients with esophageal squamous cell carcinoma
- interventionNames
- Other: Routine care as per site standard
- label
- GAC
- description
- 920 patients with gastric adenocarcinoma
- interventionNames
- Other: Routine care as per site standard
- label
- GEJAC
- description
- 580 patients with gastroesophageal junction adenocarcinoma
- interventionNames
- Other: Routine care as per site standard
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC * Planned palliative systemic first-line therapy * Age \>= 18 years * Signed informed consent (IC) * Patients answering questionnaires: IC before first therapy cycle * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle Exclusion Criteria: * No systemic therapy for ESCC, EAC, GAC or GEJAC
References
Publications (0)
Data not yet available
No reference posted for this study.